Rescue Mission Yields $3.4 Billion: Fixing Big Pharma's Hidden Assets

After Pfizer shelved mirdametinib, an experimental cancer drug, a small group of investors took it upon themselves to rescue the asset. Annette Bakker, a former J&J pharmacologist and head of the Children's Tumor Foundation, connected with Pfizer's then-chief medical officer Freda Lewis-Hall and clinicians who had positive data on mirdametinib.

The team raised $130 million, took the asset out of Pfizer, and built a company around it. The drug, rebranded as Gomekli, was later approved by the FDA in 2025, along with another shelved Pfizer compound. Merck KGaA acquired the company for $3.4 billion in July 2025.

Bakker and MIT finance professor Andrew Lo argue that this rescue is proof of a fixable market failure. Big pharma companies often bury viable drugs due to lack of internal sponsorship or resources, leaving them inaccessible to patients who need them.